Azitra (AZTR) Times Interest Earned (2022 - 2026)
Azitra (AZTR) posted Times Interest Earned of -$1056.4 for Q1 2026, down 306.64% on a QoQ basis from $511.2 in Q4 2025, and down 56.09% year-over-year from -$2405.9 in Q1 2025.
Azitra (AZTR) Times Interest Earned (2022 - 2026) Analysis & Trends
Azitra's Times Interest Earned history runs 5 years deep, the most recent figure standing at -$1056.4 for Q1 2026.
- Quarterly Times Interest Earned fell 56.09% year-over-year to -$1056.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1248.6 (down 97.17% YoY) and the FY2025 annual result came in at -$0.55, up 16.81% from the prior year.
- Times Interest Earned was -$1056.4 for Q1 2026 at Azitra, down from $511.2 in the prior quarter.
- Across five years, Times Interest Earned topped out at $511.2 in Q4 2025 and bottomed at -$1447.3 in Q4 2023.
- A 5-year average of -$400.61 and a median of -$275.5 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned plunged 5575.73% — and 2025, when it soared 217.86%.
- Azitra's Times Interest Earned stood at -$25.5 in 2022, then slumped by 5575.73% to -$1447.3 in 2023, then jumped by 70.03% to -$433.74 in 2024, then surged by 217.86% to $511.2 in 2025, then sank by 306.64% to -$1056.4 in 2026.
- Business Quant data shows AZTR's Times Interest Earned at -$1056.4 in Q1 2026, $511.2 in Q4 2025, and -$103.95 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - | -157.58 |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn | 7.60 |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn | 2.71 |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn | 22.72 |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - | -2.48 |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn | 3.88 |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - | -0.38 |
| 10 | Azitra | 2.05 Mn | 2.05 Mn | - | -1,056.37 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,056.37 |
| Dec 31, 2025 | 511.20 |
| Sep 30, 2025 | -103.95 |
| Jun 30, 2025 | -4.89 |
| Mar 31, 2025 | -676.76 |
| Dec 31, 2024 | -433.74 |
| Sep 30, 2024 | -760.64 |
| Jun 30, 2024 | -755.33 |
| Mar 31, 2024 | -717.76 |
| Dec 31, 2023 | -1,447.26 |
| Sep 30, 2023 | -709.77 |
| Jun 30, 2023 | -18.74 |
| Mar 31, 2023 | -17.35 |
| Dec 31, 2022 | -25.50 |
| Sep 30, 2022 | -75.65 |
| Jun 30, 2022 | -117.25 |